Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
120 participants
OBSERVATIONAL
2025-01-01
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Study Purpose This study aims to investigate whether serum insulin-like growth factor 1 (IGF1) can be used to improve the diagnosis of heart failure with preserved ejection fraction (HFpEF) in women, providing preliminary insights for early detection of this condition in female patients.
2. Study Procedures Information Collection: Relevant medical information will be collected during your outpatient visit or hospitalization.
Subject Identification: If you agree to participate, you will be assigned a unique study number to establish a medical record file.
Blood Sampling:
Blood samples will be collected concurrently with routine clinical blood draws (no additional needle insertions).
Volume: 10-20 mL of venous blood each time, collected on the enrollment day, 3 months, 6 months, and 12 months after enrollment.
Use of Samples: Samples will be used exclusively for this study. Follow-up Examinations: Standard HF follow-up tests (e.g., echocardiograms) will be conducted as clinically necessary. These are part of routine HF management and will not impose extra burden on you.
3. Risks and Discomforts Confidentiality: All information will be kept strictly confidential.
Minimal Risks:
Temporary pain, bruising, or tenderness at the blood draw site. Rarely, mild dizziness or (extremely rarely) needle site infection.
4. Responsibilities as a Research Subject
You are required to:
Provide truthful information about your medical history and current health status. Report any discomfort experienced during the study to the research doctor. Avoid taking restricted medications or foods as instructed. Disclose if you are currently participating in, or have recently participated in, other research studies.
5. Privacy Protection Anonymization: Blood samples will be labeled with your study number, not your name.
Confidentiality:
Identifiable information will not be disclosed to anyone outside the research team without your permission. Research staff and the sponsor are obligated to maintain your privacy. Records will be stored in locked cabinets and accessible only to authorized researchers. Regulatory agencies or ethics committees may review your data (anonymized) to ensure study compliance. No personal identifying information will be disclosed in study publications.
6. Compensation for Study-Related Injuries In the event of a study-related injury, you are entitled to compensation in accordance with Chinese law.
7. Voluntary Participation and Withdrawal You may refuse to participate or withdraw from the study at any time. Withdrawal will not affect your medical care or rights. Data collected before withdrawal will be excluded from the study results upon your request.
The researcher may terminate your participation if you fail to follow the protocol, require other treatments, experience study-related injuries, or for other medical reasons.
8. Contact Information For questions about the study, your rights, or any discomfort/injury during the study, please contact Principal Investigator: Dr. Sidong Cai via [email protected].
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Relationship Between Heart Function and Metabolism in HFpEF Patients
NCT05053256
Impact of Heart Failure Center Program on Cardiac Outcomes in Patients With Heart Failure
NCT01416285
The Correlation Between Serum PRMT5 Level and Cardiac Ultrasound Indicators in Patients With Heart Failure
NCT07050706
Hormone Deficiency in Heart Failure With Preserved Ejection Fraction
NCT02976350
Change of NLRP3 Inflammasome Expression Level, Symptoms, and Functional Status in HFpEF Patients Treated With ARNI
NCT04269057
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* female participants only;
Exclusion Criteria
* participants receiving hormone therapy
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The University of Hong Kong-Shenzhen Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cai Sidong
Assistant Research Fellow
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The University of Hong Kong-Shenzhen Hospital
Shenzhen, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
82300446
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
RCBS20231211090745071
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
8230-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.